

Uwe Kordes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/657978/publications.pdf>

Version: 2024-02-01

69
papers

2,537
citations

257450

24
h-index

197818

49
g-index

71
all docs

71
docs citations

71
times ranked

3595
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. <i>American Journal of Human Genetics</i> , 2010, 86, 279-284.	6.2	288
2	Molecular mechanisms of constitutive NF- κ B/Rel activation in Hodgkin/Reed-Sternberg cells. <i>Oncogene</i> , 1999, 18, 943-953.	5.9	265
3	Transcription factor NF- κ B is constitutively activated in acute lymphoblastic leukemia cells. <i>Leukemia</i> , 2000, 14, 399-402.	7.2	252
4	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
5	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
6	High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 185-190.	2.8	138
7	Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 176-181.	2.8	96
8	Cribriform Neuroepithelial Tumor (CRINET): A Nonrhabdoid Ventricular Tumor With INI1 Loss and Relatively Favorable Prognosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1249-1255.	1.7	92
9	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 1006-1017.	1.2	72
10	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	1.2	67
11	Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. <i>Pediatric Blood and Cancer</i> , 2006, 47, 273-278.	1.5	65
12	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). <i>Bone Marrow Transplantation</i> , 2014, 49, 370-375.	2.4	58
13	Expression of SOX9 and SOX10 in Central Neuroepithelial Tumor. <i>Journal of Neuro-Oncology</i> , 2006, 80, 151-155.	2.9	48
14	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. <i>Acta Neuropathologica</i> , 2021, 141, 291-301.	7.7	47
15	Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 373-380.	2.8	43
16	Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). <i>Pediatric Blood and Cancer</i> , 2014, 61, 919-921.	1.5	41
17	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	1.6	36
18	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.	7.7	36

#	ARTICLE	IF	CITATIONS
19	Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children. <i>Acta Neuropathologica</i> , 2015, 129, 925-927.	7.7	35
20	Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. <i>Developmental Brain Research</i> , 2005, 157, 209-213.	1.7	31
21	High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 110-120.	1.7	31
22	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. <i>European Journal of Human Genetics</i> , 2018, 26, 1083-1093.	2.8	30
23	Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. <i>Journal of Neuro-Oncology</i> , 2012, 107, 139-146.	2.9	29
24	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	4.1	27
25	The genetic landscape of choroid plexus tumors in children and adults. <i>Neuro-Oncology</i> , 2021, 23, 650-660.	1.2	26
26	Ectopic Craniopharyngioma. <i>Klinische Padiatrie</i> , 2011, 223, 176-177.	0.6	25
27	Radiation therapy for choroid plexus carcinoma patients with Li-Fraumeni syndrome: advantageous or detrimental?. <i>Anticancer Research</i> , 2015, 35, 3013-7.	1.1	21
28	A complex karyotype in an atypical teratoid/rhabdoid tumor: case report and review of the literature. <i>Journal of Neuro-Oncology</i> , 2011, 104, 375-380.	2.9	20
29	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. <i>Familial Cancer</i> , 2021, 20, 305-316.	1.9	20
30	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. <i>Lancet Oncology</i> , The, 2018, 19, e419-e428.	10.7	16
31	Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). <i>European Journal of Cancer</i> , 2021, 142, 112-122.	2.8	15
32	<sc>SMARCA4</sc>-deficient rhabdoid tumours show intermediate molecular features between <sc>SMARCB1</sc>-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2021, 255, 1-15.	4.5	14
33	Co-occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 627-637.	1.2	13
34	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. <i>Familial Cancer</i> , 2021, 20, 327-336.	1.9	13
35	ATRT comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance. <i>Acta Neuropathologica</i> , 2022, 143, 697-711.	7.7	13
36	Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression. <i>Journal of Neuro-Oncology</i> , 2013, 112, 191-197.	2.9	12

#	ARTICLE	IF	CITATIONS
37	Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents. <i>Journal of Neuro-Oncology</i> , 2012, 109, 449-455.	2.9	11
38	Methylation of the hTERT promoter is frequent in choroid plexus tumors but not of independent prognostic value. <i>Journal of Neuro-Oncology</i> , 2014, 119, 215-216.	2.9	11
39	Final results of the Choroid Plexus Tumor study CPT-SIOP-2000. <i>Journal of Neuro-Oncology</i> , 2022, 156, 599-613.	2.9	11
40	Erythrocytapheresis: Do Not Forget a Useful Therapy!. <i>Transfusion Medicine and Hemotherapy</i> , 2008, 35, 24-30.	1.6	10
41	Epigenetics impacts upon prognosis and clinical management of choroid plexus tumors. <i>Journal of Neuro-Oncology</i> , 2020, 148, 39-45.	2.9	10
42	Neonatal cholestasis and glucose-6-phosphate dehydrogenase deficiency. <i>Pediatric Blood and Cancer</i> , 2010, 54, 758-760.	1.5	9
43	Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population. <i>Cancers</i> , 2022, 14, 2185.	3.7	9
44	Parvovirus B19 infection and autoimmune hepatitis in a child with sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2011, 56, 323-324.	1.5	7
45	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	7.7	7
46	Spatial molecular profiling of a central nervous system low-grade diffusely infiltrative tumour with INI1 deficiency featuring a high-grade atypical teratoid/rhabdoid tumour component. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	7
47	Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study. <i>Clinical Oral Investigations</i> , 2018, 22, 1541-1549.	3.0	6
48	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. <i>Acta Neuropathologica</i> , 2021, 142, 361-374.	7.7	6
49	Atypical Teratoid/Rhabdoid Tumor (AT/RT) With Molecular Features of Pleomorphic Xanthoastrocytoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1228-1234.	3.7	5
50	Transposable element insertion as a mechanism of <i>SMARCB1</i> inactivation in atypical teratoid/rhabdoid tumor. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 586-590.	2.8	5
51	Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2021, 142, 591-593.	7.7	5
52	Low-grade diffusely infiltrative tumour (LGDIT), SMARCB1-mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	5
53	Long-term treatment with deferiprone in a L1 veteran. <i>European Journal of Haematology</i> , 2005, 74, 523-525.	2.2	4
54	Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1. <i>Anticancer Research</i> , 2019, 39, 827-831.	1.1	4

#	ARTICLE	IF	CITATIONS
55	PTCT-01 INTERCONTINENTAL MULTIDISCIPLINARY DATA COLLECTION AND TREATMENT OPTIMIZATION STUDY FOR PATIENTS WITH CHOROID PLEXUS TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v186.1-v186.	1.2	3
56	EMBR-08. CHOROID PLEXUS TUMORS IN 2018: THE CPT-SIOP EXPERIENCE AND LONG-TERM OUTCOME. <i>Neuro-Oncology</i> , 2018, 20, i70-i70.	1.2	3
57	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1277-1283.	3.7	3
58	Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. <i>Child's Nervous System</i> , 2018, 34, 581-584.	1.1	2
59	Gremlins of all brain tumors: germinomas and nongerminomatous germ cell tumors. <i>Critical Reviews in Neurosurgery: CR</i> , 1998, 8, 1-5.	0.2	1
60	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	1.2	1
61	ATRT-06. CLINICAL AND MOLECULAR RISK FACTORS IN CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMOUR (AT/RT) - EVIDENCE FROM THE EU-RHAB REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i28-i28.	1.2	0
62	Evidence for a low-penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29185.	1.5	0
63	<i>Neuroonkologie.</i> , 2009, , 215-239.		0
64	<i>Neuroonkologie.</i> , 2014, , 277-304.		0
65	Updated dataset of germline mutations within the SWI/SNF complex predicting age of tumor onset and type of disease. <i>Klinische Padiatrie</i> , 2017, 229, .	0.6	0
66	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29594.	1.5	0
67	ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. <i>Neuro-Oncology</i> , 2022, 24, i3-i4.	1.2	0
68	DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge. <i>Neuro-Oncology</i> , 2022, 24, i28-i28.	1.2	0
69	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations and TP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i4-i4.	1.2	0